Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Multiple Myeloma 12Lymphoma, Non-Hodgkin 7Carcinoma, Non-Small-Cell Lung 5Lymphoma, Large B-Cell, Diffuse 4Breast Neoplasms 4Recurrence 3Melanoma 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Urinary Bladder Neoplasms 2Lymphoma, Follicular 2Cytokine Release Syndrome 2Craniopharyngioma 2Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Sarcoma 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasms 1Nasopharyngeal Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1

Interventions

Rituximab 53Cyclophosphamide 50Lenalidomide 41fludarabine 24obinutuzumab 23Prednisone 19Bendamustine Hydrochloride 19Magnetic Resonance Spectroscopy 18Vincristine 17Doxorubicin 16fludarabine phosphate 15Specimen Handling 15zanubrutinib 13Biopsy 12tazemetostat 10ibrutinib 10Whole-Body Irradiation 10pembrolizumab 9Peripheral Blood Stem Cell Transplantation 9venetoclax 8Mycophenolic Acid 7Etoposide 7axicabtagene ciloleucel 6Radiotherapy 6CT-P10 6Therapeutics 5R-CHOP protocol 5tafasitamab 4polatuzumab vedotin 4acalabrutinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, Follicular × tocilizumab × 1 year × Clear all
NCT04246086 2026-03-19

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma

Hoffmann-La Roche

Phase 1/2 Active not recruiting
237 enrolled
Lymphoid

Lymphoma, Follicular

NCT04007029 2025-09-05

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Jonsson Comprehensive Cancer Center

Phase 1 Active not recruiting
24 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡